|
|
Line 272: |
Line 272: |
| <br> | | <br> |
|
| |
|
| ='''Using Alternative Nicotine Products by People Living With Mental Health Challenges to Aid Smoking Cessation'''= | | ='''Using Alternative Nicotine Products by People Living With ''Physical Health Challenges'' to Aid Smoking Cessation'''= |
| | |
| | ===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== |
| | *This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. |
| | <br> |
| | |
| | ='''Using Alternative Nicotine Products by People Living With ''Mental Health Challenges'' to Aid Smoking Cessation'''= |
|
| |
|
| ===2021: [https://academic.oup.com/ntr/article/23/7/1113/6168972 A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes]=== | | ===2021: [https://academic.oup.com/ntr/article/23/7/1113/6168972 A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes]=== |
Line 280: |
Line 286: |
| *A high strength nicotine e-cigarette has the potential to help people with schizophrenia spectrum disorders to quit or reduce smoking. | | *A high strength nicotine e-cigarette has the potential to help people with schizophrenia spectrum disorders to quit or reduce smoking. |
| *[https://scholar.google.com/scholar_url?url=https://academic.oup.com/ntr/article-pdf/23/7/1113/38521536/ntab005.pdf&hl=en&sa=T&oi=ucasa&ct=ufr&ei=yBQBYYa-NZHsyQTPkaSoDg&scisig=AAGBfm3GpEvV3isL4-eiS-xFao9KegDu2Q PDF Version] | | *[https://scholar.google.com/scholar_url?url=https://academic.oup.com/ntr/article-pdf/23/7/1113/38521536/ntab005.pdf&hl=en&sa=T&oi=ucasa&ct=ufr&ei=yBQBYYa-NZHsyQTPkaSoDg&scisig=AAGBfm3GpEvV3isL4-eiS-xFao9KegDu2Q PDF Version] |
| *Citation: Pasquale Caponnetto, PhD, Jennifer DiPiazza, PhD, Jason Kim, MD, Marilena Maglia, Lyc Psych, Riccardo Polosa, MD, PhD, A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes, Nicotine & Tobacco Research, Volume 23, Issue 7, July 2021, Pages 1113–1122, doi:10.1093/ntr/ntab005
| |
| *Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength.
| |
| <br> | | <br> |
|
| |
|